Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia

by Dany Habr, Manmohan Singh, Roberto Uehara
Published 2023-12-01

Correction: Patients at the Heart of the Scientific Dialogue: An Industry Perspective

by Dany Habr, Brittany Wolf Gianares, Kristine W. Schuler, Dheepa Chari
Published 2023-02-01

Patients at the Heart of the Scientific Dialogue: An Industry Perspective

by Dany Habr, Brittany Wolf Gianares, Kristine W. Schuler, Dheepa Chari
Published 2023-01-01

Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study

by Jong Wook Lee, Sung-Soo Yoon, Zhi Xiang Shen, Arnold Ganser, Hui-Chi Hsu, Ali El-Ali, Dany Habr, Nicolas Martin, John B. Porter
Published 2013-07-01

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: R...

by John Porter, Donald K. Bowden, Marina Economou, Jacques Troncy, Arnold Ganser, Dany Habr, Nicolas Martin, Adam Gater, Diana Rofail, Linda Abetz-Webb, Helen Lau, Maria Domenica Cappellini
Published 2012-01-01

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

by Norbert Gattermann, Carlo Finelli, Matteo Della Porta, Pierre Fenaux, Michael Stadler, Agnes Guerci-Bresler, Mathias Schmid, Kerry Taylor, Dominique Vassilieff, Dany Habr, Andrea Marcellari, Bernard Roubert, Christian Rose
Published 2012-09-01

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major

by Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, Vip Viprakasit, Mohsen S. Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher
Published 2012-06-01

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

by Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher
Published 2011-01-01

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

by Maria Domenica Cappellini, John Porter, Amal El-Beshlawy, Chi-Kong Li, John F. Seymour, Mohsen Elalfy, Norbert Gattermann, Stéphane Giraudier, Jong-Wook Lee, Lee Lee Chan, Kai-Hsin Lin, Christian Rose, Ali Taher, Swee Lay Thein, Vip Viprakasit, Dany Habr, Gabor Domokos, Bernard Roubert, Antonis Kattamis
Published 2010-04-01

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

by Srdan Verstovsek, Alessandro M. Vannucchi, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Keita Kirito, Carlos Besses, Masayuki Hino, Beatriz Moiraghi, Carole B. Miller, Mario Cazzola, Vittorio Rosti, Igor Blau, Ruben Mesa, Mark M. Jones, Huiling Zhen, Jingjin Li, Nathalie Francillard, Dany Habr, Jean-Jacques Kiladjian
Published 2016-07-01